Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
5-day change
1st Jan Change
49.86
USD
+4.03%
+4.90%
-16.71%
Sales 2024 *
793M
Sales 2025 *
1.18B
Capitalization
6.05B
Net income 2024 *
-121M
Net income 2025 *
159M
EV / Sales 2024 *
7.09
x
Net cash position
2024
*
420M
Net cash position
2025
*
711M
EV / Sales 2025 *
4.54
x P/E ratio 2024 *
-50.1
x
P/E ratio 2025 *
41
x
Employees
704
Yield 2024 *
-
Yield 2025 *
-
Free-Float
86.78%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment
Apr. 26
MT
Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency
Apr. 26
CI
Wedbush Cuts Price Target on Apellis Pharmaceuticals to $57 From $67, Keeps Neutral Rating
Apr. 17
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing
Apr. 09
MT
Transcript : Apellis Pharmaceuticals, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-08-2024 12:45 PM
Apr. 08
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing
Mar. 21
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing
Mar. 20
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $645,838, According to a Recent SEC Filing
Mar. 14
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $4,297,549, According to a Recent SEC Filing
Mar. 11
MT
Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024
Mar. 11
CI
JPMorgan Adjusts Price Target on Apellis Pharmaceuticals to $79 From $78, Maintains Overweight Rating
Mar. 06
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $16,028,706, According to a Recent SEC Filing
Mar. 05
MT
Transcript : Apellis Pharmaceuticals, Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 11:00 AM
Mar. 05
Transcript : Apellis Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-03-2024 through Mar-06-2024
Mar. 04
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer
Mar. 04
MT
More news
Wedbush Cuts Price Target on Apellis Pharmaceuticals to $57 From $67, Keeps Neutral Rating
Apr. 17
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing
Apr. 09
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing
Mar. 21
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing
Mar. 20
MT
JPMorgan Adjusts Price Target on Apellis Pharmaceuticals to $79 From $78, Maintains Overweight Rating
Mar. 06
MT
More recommendations
1 day +4.03%
1 week +4.90%
Current month -15.18%
1 month -14.75%
3 months -22.14%
6 months +4.88%
Current year -16.71%
More quotes
Managers
Title Age Since
Founder
54
09-09-24
Founder
51
09-09-24
Director of Finance/CFO
53
17-09-30
Members of the board
Title Age Since
Founder
51
09-09-24
Director/Board Member
65
13-06-30
Director/Board Member
52
10-02-28
More insiders
Date
Price
Change
Volume
24-04-26
49.86
+4.03%
1,215,021
24-04-25
47.93
-4.01%
1,122,466
24-04-24
49.93
+2.48%
1,245,776
24-04-23
48.72
+2.27%
1,184,940
24-04-22
47.64
+0.23%
784,535
Delayed Quote
Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Companyâs approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.
More about the company
Last Close Price
49.86
USD
Average target price
82.01
USD
Spread / Average Target
+64.48%
Consensus
1st Jan change
Capi.
-16.71% 6.01B -4.66% 86.13B +1.32% 39.82B -19.27% 30.42B +57.86% 25.23B -16.09% 15.35B -9.14% 11.95B -17.69% 11.6B -43.00% 11.51B +5.24% 8.71B
Biopharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1